0001662002-16-000002.txt : 20161205 0001662002-16-000002.hdr.sgml : 20161205 20161205132208 ACCESSION NUMBER: 0001662002-16-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20161205 DATE AS OF CHANGE: 20161205 EFFECTIVENESS DATE: 20161205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nohla Therapeutics Inc. CENTRAL INDEX KEY: 0001662002 IRS NUMBER: 475261773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-275626 FILM NUMBER: 162033295 BUSINESS ADDRESS: STREET 1: 1616 EASTLAKE AVENUE EAST STREET 2: SUITE 202 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 61430589444 MAIL ADDRESS: STREET 1: 1616 EASTLAKE AVENUE EAST STREET 2: SUITE 202 CITY: SEATTLE STATE: WA ZIP: 98102 D 1 primary_doc.xml X0707 D LIVE 0001662002 Nohla Therapeutics Inc. 1616 EASTLAKE AVENUE EAST SUITE 202 SEATTLE WA WASHINGTON 98102 61430589444 DELAWARE Cytomatrix Therapeutics, Inc. None Corporation true 2015 Lawrence Gozlan 1616 Eastlake Avenue East Suite 202 Seattle WA WASHINGTON 98102 Director Michael Sistenich 1616 Eastlake Avenue East Suite 202 Seattle WA WASHINGTON 98102 Executive Officer Director Steven Gillis 1616 Eastlake Avenue East Suite 202 Seattle WA WASHINGTON 98102 Director Brian Daniels 1616 Eastlake Avenue East Suite 202 Seattle WA WASHINGTON 98102 Director Darren Scotti 1616 Eastlake Avenue East Suite 202 Seattle WA WASHINGTON 98102 Executive Officer Biotechnology Decline to Disclose 06b false 2016-11-18 true true true false 0 41639800 11999999 29639801 These amounts exclude issuances of Company securities pursuant to Regulation S promulgated under the Securities Act of 1933, as amended false 3 0 0 0 false Nohla Therapeutics Inc. /s/ Darren Scotti Darren Scotti Secretary 2016-12-05